Effect of Bortezomib combined with chemotherapeutic medicine on hepatic and colonic cancer cell lines
10.3969/j.issn.1002-3070.2013.06.004
- VernacularTitle:硼替佐米联合化疗药物对肝癌、结肠癌细胞的抑制作用研究
- Author:
Yanjie CHU
;
Bingrong LIU
- Publication Type:Journal Article
- Keywords:
Bortezomib;
Arsenous acid;
Chemotherapy;
Drug-resistance
- From:
Practical Oncology Journal
2013;(6):496-499
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the influence of arsenous acid on hepatic and colonic cancer cell lines BEL-7402 and HT-29 .The effect of bortezomib combined with chemotherapeutic medicine and the optimal combination plan of them were also investigated .Methods We detected cell proliferation by MTT to get the inhi-bition rate of two cell lines and further to determine IC 50 ( inhibitory concentration50%) of 5-Fu,oxaliplatin or arsenous acid;preincubated cancer cells for 2 h、4 h or 8 h by bortezomib .Chemotheraputic medicine were com-bined respectively .The cell proliferation and apoptosis were analysed by MTT ,TUNEL and Annexin V -PI.Re-sult s The 24 h inhibition rate of arsenous acid to BEL -7402 and HT-29 was:0.59 ±0.09、0.71 ±0.12 re-spectively;the IC50 of 5 -Fu,Oxaliplatin or arsenous acid to BEL -7402 was:5.33 ±0.07 mg/L,28.73 ± 0.72 mg/L,25.93 ±4.05 mg/L, while to HT -29 was:7.33 ±1.13 mg/L、53.94 ±1.23 mg/L,21.93 ± 2.05 mg/L.Both inhibition rate and apoptosis rate were enhanced when chemotheraputic medicine was combined with bortezomib .Co nclusion Arsenous acid can inhibit the growth of cancer cells obviously;the susceptibility of each chemotherapy medicine can be strengthened significantly when it is combined with bortezomib ,P<0.05.
